Document is current
Any future updates will be listed below
-
Authors
Zhao, Ruiyue
Lv, Jie
Li, Mingzhao
Xu, Siran
Liang, Wenhua
Lin, Xinqing
Gu, Di
Zeng, Guohua
Jin, Wenbin
Yan, Qingsong
Zhong, Huizhen
Alexoff, David
Ploessl, Karl
Zhu, Lin
Kung, Hank F.
Wang, Xinlu https://orcid.org/0000-0003-1997-5687
-
Funding
Funding for this research was provided by:
Guangdong regional joint fund (2022A1515110941)
Medical Science and Technology Research of Guangdong Province (202211195047503)
Guangzhou basic and applied basic research (2023A04J1196, 2024A03J1228, 2024A03J1157)
- License Information
-
More Information
Article History
Received: 16 May 2024
Accepted: 6 October 2024
First Online: 18 October 2024
Declarations
:
: This study was approved by the Clinical Research Ethics Committee of the First Affiliated Hospital of Guangzhou Medical University (EC-2023-029) and it was conducted in accordance with the principles of the Declaration of Helsinki.
: Informed consent was obtained from all participants included in the study.
: David Alexoff, Karl Ploessl and Hank F. Kung are employees of Five Eleven Pharma, and Hank Kung is also the found and board of the company, which holds the patent rights for [177Lu]Lu-P15-073 and related technology. Other authors have no conflicts of interest or relevant financial activities to disclose.
